Description
The LMBRD1 c.1056delG (p.Asn353IlefsTer18) variant results in a frameshift and is predicted to result in premature termination of the protein. Across a selection of the available literature, the p.Asn353IlefsTer18 variant has been identified in 11 individuals with disorders of intracellular cobalamin metabolism, including in a homozygous state in eight and in a compound heterozygous state in three (Rutsch et al. 2009; Miousse et al. 2011; Constantinou et al. 2016). An additional deceased proband with cobalamin deficiency was found to carry the p.Asn353IlefsTer18 variant and a second variant in the MTR gene, suggesting the possibility of digenic inheritance (Farwell Gonzalez et al. 2015). Phenotypic symptoms cover a wide range of symptoms including failure to thrive, neutropenia, developmental delay, stomatitis, megaloblastic anemia, and feeding difficulties; however, some patients may show asymptomatic long-term survival (Rutsch et al. 2009). Control data are unavailable for this variant, which is reported at a frequency of 0.00109 in the European American population of the Exome Sequencing Project. Transfection of immortalized fibroblasts from a compound heterozygous proband and a homozygous proband with wildtype LMBD1 was able to rescue the biochemical intracellular cobalamin pathway F (cblF) phenotype (Rutsch et al. 2009). Based on the collective evidence and the potential impact of frameshift variants, the p.Asn353IlefsTer18 variant is classified as pathogenic for disorders of intracellular cobalamin metabolism. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
| # | Sample | Method | Observation |
|---|
| Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
|---|
| 1 | germline | unknown | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |
